CD8A and neoplasm: To further investigate the mechanisms underlying the anti-tumor efficacy of ODN1826 or α-GalCer in the immunized mice that were injected with TC-1/A9 tumor cells, we depleted in vivo CD4+, CD8+, or NK1.1+ cells with monoclonal antibodies and MΦs by administration of carrageenan.